RRs and 95% CIs for (A) 2-year relapse risk and (B) 5-year OS, according to a subgroup analysis of CBF-AML.

Abstract

<p>The number of included studies, number of patients in the included studies, and percentage of patients with <i>KIT</i> mutations in the included studies are listed.</p